Stéroïdes intra-vitréens et intraveineux dans un cas de syndrome d’Idiopathic Retinitis, Vasculitis and Neuroretinitis (IRVAN)

Ennouri, A; Makhoul, Dorine; Nubourgh, Isabelle; Mistryh, S.; Caspers, Laure; Willermain, François

doi:10.1016/j.jfo.2013.04.010

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Systemic drugs include corticosteroids, DMARDs, and biologics, while ocular treatments include laser photocoagulation, intravitreal anti-VEGF injections, ocular steroids, surgery, and ablative procedures. 12–14,28,30,31,33,37,39,46,47,50,51…”

Section: Discussionmentioning

confidence: 99%

Comprehensive overview of IRVAN syndrome: a structured review of Case Reports and Case Series

Khan

Shahzad

et al. 2022

Ophthalmol Eye Dis

View full text Add to dashboard Cite

Idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome is a rare spectrum of retinal vasculitis, aneurysms, and neuroretinitis affecting young individuals in their third decade. Most of our current knowledge is based on case reports, case series, and a handful of collaborative studies. There is much diversity in treatment approaches and outcomes in the reported literature. We have aggregated published case reports and case series into quantitative and narrative synthesis to draw evidence-based conclusions toward clinical features, atypical and rare findings, systemic associations, disease course, and treatment outcomes. The analysis suggested the disease mostly affects young individuals with a female predilection. Anterior chamber and vitreous inflammation are common than previously believed. The most prevalent pattern of retinal vasculitis in IRVAN eyes is mixed vasculitis, followed by arteritis and phlebitis. Most eyes at the time of presentation have capillary nonperfusion and require treatment. Most eyes retain good visual acuity; however, treatment is required to maintain visual function. Intravitreal antivascular endothelial growth factors administered as an adjunct to retinal laser photocoagulation are more likely to improve visual outcomes. Besides, we have discussed the different hypotheses on the etiopathogenesis of the disease and stronger evidence suggests an inflammatory origin of the disease.

show abstract